Attitudes, Perceptions and Barriers in Implementing Therapeutic Drug Monitoring for Anti-TNFs in Inflammatory Bowel Disease: a Survey from the Middle East

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2024 Feb 26

PMID 38406794

Authors

Gaurav B Nigam

Kelly Chatten

Ala Sharara

Talal Al-Taweel

Othman Alharbi

Hussein Elamin

Sameer Al Awadhi

Vito Annese

Jimmy K Limdi

Affiliations

Soon will be listed here.

Abstract

Background: A growing body of evidence underscores the beneficial impact of therapeutic drug monitoring (TDM) on the efficacy and cost-effectiveness of anti-tumour necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD).

Objectives: We surveyed clinician attitudes, perceptions and barriers related to TDM in IBD in the Middle East.

Design: A 15-question survey was distributed through national gastroenterological societies in five Middle Eastern countries (UAE, Saudi Arabia, Kuwait, Lebanon and Egypt).

Methods: Data on clinician characteristics, demographics, utilization patterns and obstacles related to the adoption of TDM with anti-TNFs were gathered. Logistic regression analysis was used to predict factors influencing the utilization of TDM.

Results: Among 211 respondents (82% male), 82% were consultants, 8% were physicians with an interest in gastroenterology (GI), and 6% were GI trainees. Of these, 152 met inclusion criteria, treating >5 IBD patients per month and ⩾1 with an anti-TNF per month. TDM was used in clinical practice by 78% (95% CI: 71-85) of respondents. TDM was utilized following the loss of response (LOR) in 93%, for primary non-response (PNR) in 40% and before restarting anti-TNF therapy after a drug holiday in 33% of respondents, while 34% used TDM proactively. No specific factors were associated with the use of TDM. Barriers to TDM use included cost (85%), time lag to results (71%) and lack of insurance reimbursement (65%). Overall knowledge of TDM (70%), interpretation and actioning of results (76%) or awareness of clinical guidelines (57%) were not perceived as barriers. If barriers were removed, 95% would use TDM more frequently; 93% for LOR, 60% for PNR, 50% when restarting after a drug holiday, and 54% would use TDM proactively.

Conclusion: Most gastroenterologists use TDM for LOR, with cost, time lag and insurance reimbursement being significant barriers. Addressing these barriers would increase the judicious use of reactive and proactive TDM to optimize anti-TNF therapy in IBD.

References

Patel R, Nigam G, Jatale R, Desai D, Makharia G, Ahuja V . An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. Indian J Gastroenterol. 2020; 39(2):176-185. PMC: 7297832. DOI: 10.1007/s12664-020-01047-6. View

Kennedy N, Heap G, Green H, Hamilton B, Bewshea C, Walker G . Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019; 4(5):341-353. DOI: 10.1016/S2468-1253(19)30012-3. View

Bhat S, Limdi J, Cross R, Farraye F . Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease. Dig Dis Sci. 2021; 66(8):2513-2532. DOI: 10.1007/s10620-021-07114-y. View

Papamichael K, Cheifetz A, Melmed G, Irving P, Vande Casteele N, Kozuch P . Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019; 17(9):1655-1668.e3. PMC: 6661210. DOI: 10.1016/j.cgh.2019.03.037. View

Papamichael K, Gils A, Rutgeerts P, Levesque B, Vermeire S, Sandborn W . Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2014; 21(1):182-97. DOI: 10.1097/MIB.0000000000000202. View

Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert J, Raine T . ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2019; 14(1):4-22. DOI: 10.1093/ecco-jcc/jjz180. View

Brandse J, Mathot R, van der Kleij D, Rispens T, Ashruf Y, Jansen J . Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2015; 14(2):251-8.e1-2. DOI: 10.1016/j.cgh.2015.10.029. View

Amiot A, Hulin A, Belhassan M, Andre C, Gagniere C, Le Baleur Y . Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission. Clin Res Hepatol Gastroenterol. 2015; 40(1):90-8. DOI: 10.1016/j.clinre.2015.05.019. View

Vermeire S, Dreesen E, Papamichael K, Dubinsky M . How, When, and for Whom Should We Perform Therapeutic Drug Monitoring?. Clin Gastroenterol Hepatol. 2019; 18(6):1291-1299. DOI: 10.1016/j.cgh.2019.09.041. View

10.

Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar A, Khassouan A . First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol. 2020; 26(43):6710-6769. PMC: 7684461. DOI: 10.3748/wjg.v26.i43.6710. View

11.

Alric H, Amiot A, Kirchgesner J, Treton X, Allez M, Bouhnik Y . The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020; 51(10):948-957. DOI: 10.1111/apt.15706. View

12.

AlRuthia Y, Alharbi O, Aljebreen A, Azzam N, Almadi M, Bahari O . Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia. Cost Eff Resour Alloc. 2019; 17:25. PMC: 6894268. DOI: 10.1186/s12962-019-0194-3. View

13.

Strik A, Berends S, Lowenberg M . Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?. Expert Rev Clin Pharmacol. 2019; 12(9):885-891. DOI: 10.1080/17512433.2019.1642745. View

14.

DHaens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B . Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology. 2018; 154(5):1343-1351.e1. DOI: 10.1053/j.gastro.2018.01.004. View

15.

Papamichael K, Rakowsky S, Rivera C, Cheifetz A, Osterman M . Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther. 2017; 47(4):478-484. PMC: 6535226. DOI: 10.1111/apt.14458. View

16.

Levesque B, Greenberg G, Zou G, Sandborn W, Singh S, Hauenstein S . A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther. 2014; 39(10):1126-35. DOI: 10.1111/apt.12733. View

17.

Shah S, Colombel J, Sands B, Narula N . Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016; 14(9):1245-1255.e8. DOI: 10.1016/j.cgh.2016.01.015. View

18.

Papamichael K, Cheifetz A . Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2017; 7(4):289-300. PMC: 5369499. DOI: 10.1136/flgastro-2016-100685. View

19.

Nigam G, Nayeemuddin S, Kontopantelis E, Hayee B, Limdi J . UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Frontline Gastroenterol. 2021; 12(1):22-29. PMC: 7802494. DOI: 10.1136/flgastro-2019-101372. View

20.

Lega S, Phan B, Rosenthal C, Gordon J, Haddad N, Pittman N . Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD. Inflamm Bowel Dis. 2018; 25(1):134-141. DOI: 10.1093/ibd/izy203. View